Wegovy and Ozempic are the same molecule, made by the same company, in the same kind of pen. That fact drives one of the most-searched questions in this category, and it usually arrives attached to an assumption: if the drug is identical, take whichever version is cheaper or easier to get. The assumption survives about as long as it takes to read the two prescribing informations side by side. The dose ceilings differ by a factor of three, the indication lists overlap without either containing the other, and the weight result that made semaglutide famous was measured in a population that would not qualify for the diabetes brand at all — which is the subject of the STEP 2 article.
What each label actually says
Ozempic injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.[1] Every clause contains the words “type 2 diabetes.” Weight is not an indication.
Wegovy injection is indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; to reduce excess body weight and maintain the reduction in adults and in patients aged 12 and over with obesity, or adults with overweight plus a weight-related condition; and for noncirrhotic metabolic dysfunction-associated steatohepatitis with stage F2 to F3 fibrosis, under accelerated approval.[2]
So the kidney indication belongs to Ozempic alone, and the liver indication, the adolescent indication and every weight indication belong to Wegovy alone. Neither list is a superset. Both labels also now carry an oral tablet presentation, and the routes are compared in the oral article.
The ladders separate at 2 mg
Ozempic starts at 0.25 mg once weekly for four weeks, moves to 0.5 mg, and offers 0.5, 1 or 2 mg as maintenance chosen on glycemic control. The label states a maximum of 2 mg once weekly. In chronic kidney disease the maintenance dose is 1 mg.[1]
Wegovy runs 0.25, 0.5, 1 and 1.7 mg in four-week blocks, reaching 2.4 mg at week 17, with 1.7 mg also a labeled maintenance dose. Above that, for adults tolerating 2.4 mg for at least four weeks in whom more reduction is clinically indicated, the label permits escalation to a maximum of 7.2 mg once weekly.[2] Rung by rung, that ladder is read in the dose article.
A month on Ozempic at its ceiling delivers 8 mg of semaglutide. A month of Wegovy at 2.4 mg delivers 9.6 mg, and at 7.2 mg delivers 28.8 mg. Any price comparison that treats a box as a box is comparing different quantities of the same drug.
Both brands now have a tablet, and the tablets are not equivalent either
Wegovy tablets start at 1.5 mg once daily and climb to a maintenance dosage of 25 mg once daily, taken on an empty stomach with no more than four ounces of water and nothing else by mouth for at least 30 minutes. The label instructs that patients who cannot tolerate 25 mg be considered for Wegovy injection 1.7 mg weekly instead.[2] The tablet is labeled for cardiovascular risk reduction and weight reduction in adults only — not for the adolescent or MASH indications the injection carries.
The oral semaglutide product on the diabetes side is labeled for glycemic control and for cardiovascular risk reduction in adults with type 2 diabetes at high risk, which is again a different list.[9] The 25 mg oral dose was tested in a 71-week placebo-controlled trial of 307 adults without diabetes: mean weight change at week 64 was −13.6% against −2.2% on placebo, with gastrointestinal adverse events in 74.0% against 42.2%.[10]
What the extra milligrams bought
STEP UP randomized 1,407 adults with obesity and without diabetes 5:1:1 to semaglutide 7.2 mg, semaglutide 2.4 mg or placebo for 72 weeks. Mean weight change was −18.7% on 7.2 mg against −15.6% on 2.4 mg and −3.9% on placebo, an estimated treatment difference between the two active doses of −3.1% (95% CI, −4.7 to −1.6).[3]
Three times the dose, three percentage points. The tolerability moved further than the efficacy did: gastrointestinal adverse events occurred in 70.8% on 7.2 mg against 61.2% on 2.4 mg, and dysaesthesia — altered or unpleasant sensation — in 22.9% against 6.0% and 0.5% on placebo.[3] The higher ceiling is a real option for people who stall, and it is not a proportional upgrade.
The outcome trials behind each brand are not the same shape
Wegovy’s cardiovascular claim rests on SELECT, an event-driven superiority trial in 17,604 patients aged 45 and over with preexisting cardiovascular disease, a body-mass index of 27 or greater and no diabetes. The primary composite occurred in 6.5% on semaglutide 2.4 mg against 8.0% on placebo, a hazard ratio of 0.80 (95% CI, 0.72 to 0.90; P < 0.001).[4] The trial is unpacked in the SELECT article.
Ozempic’s cardiovascular claim rests on SUSTAIN-6, which randomized 3,297 patients with type 2 diabetes to semaglutide 0.5 or 1.0 mg or placebo for 104 weeks under a noninferiority hypothesis. The primary composite occurred in 6.6% against 8.9%, a hazard ratio of 0.74 (95% CI, 0.58 to 0.95).[5] The same trial recorded retinopathy complications significantly more often on semaglutide (hazard ratio 1.76; 95% CI, 1.11 to 2.78; P = 0.02), a signal followed up in the eye article.
The kidney indication comes from FLOW, which randomized 3,533 patients with type 2 diabetes and chronic kidney disease to semaglutide 1.0 mg or placebo and was stopped early. Major kidney disease events were 24% lower (hazard ratio 0.76; 95% CI, 0.66 to 0.88; P = 0.0003), with all-cause death 20% lower.[6] The liver indication comes from a 1,197-patient trial in biopsy-defined MASH, where steatohepatitis resolved without fibrosis worsening in 62.9% on semaglutide 2.4 mg against 34.3% on placebo at week 72.[7]
Why the prices differ, and what that is evidence of
Nothing about the molecule explains the price gap. The clearest demonstration is what happened when the prices were set administratively rather than commercially: the Centers for Medicare & Medicaid Services published separate 30-day maximum fair prices for Ozempic, Rybelsus and Wegovy under the 2027 negotiation round, and those prices differed from the $245 per month most-favored-nation price announced for the class in late 2025.[8] Three brand names, one active ingredient, and a separately administered price attached to each.
What separates them is the channel. A diabetes product is reimbursed through decades of established coverage; a weight product has spent most of its existence outside it, which is the structural story told in the two-approvals article. Advertised cash figures on either brand move month to month, so a published number is only as good as its date — the standing rates this site tracks are on the semaglutide board.
What neither label licenses
Both sets of results above were produced with an approved product at a labeled dose. Compounded semaglutide is not FDA-approved and is not reviewed by the FDA for safety, efficacy or quality before dispensing, and a compounded vial has no indication, no approved maximum and no outcome trial of its own — the distinction is set out in the compounding article.
The practical reading is narrow. The two brands are not interchangeable because their labels are not interchangeable, the dose a prescription is written for matters more than the name on the pen, and anyone comparing monthly prices should first check how many milligrams each month contains. How figures here are established before publication is described in the methodology.